B · Normal
[Drug R&D company Sellas Life Sciences soared 220% at the opening] November 17th, drug R&D company Sellas Life Sciences soared 220% at the opening. The company said on Tuesday that its experimental vaccine against a blood cancer achieved positive results in a late-stage clinical trial, helping patients significantly extend their survival time.
Global market intelligence 🕐 2026-11-17 22:36

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet